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Delta-like protein 3 (DLL3) is highly expressed in solid tumors, including neuroendocrine carcinomas/neuroendocrine tumors (NEC/
NET). Rovalpituzumab tesirine (Rova-T) is a DLL3-targeting antibody-drug conjugate. Patients with NECs and other advanced DLL3expressing tumors were enrolled in this phase I/II study (NCT02709889). The primary endpoint was safety. Two hundred patients
were enrolled: 101 with NEC/NET (large-cell NEC, gastroenteropancreatic NEC, neuroendocrine prostate cancer, and other NEC/NET)
and 99 with other solid tumors (melanoma, medullary thyroid cancer [MTC], glioblastoma, and other). The recommended phase II
dose (RP2D) was 0.3 mg/kg every 6 weeks (q6w) for two cycles. At the RP2D, grade 3/4 adverse events included anemia (17%),
thrombocytopenia (15%), and elevated aspartate aminotransferase (8%). Responses were conﬁrmed in 15/145 patients (10%)
treated at 0.3 mg/kg, including 9/69 patients (13%) with NEC/NET. Rova-T at 0.3 mg/kg q6w had manageable toxicity, with
antitumor activity observed in patients with NEC/NET, melanoma, MTC, and glioblastoma.
npj Precision Oncology (2021)5:74 ; https://doi.org/10.1038/s41698-021-00214-y

INTRODUCTION
Delta-like protein 3 (DLL3) is a ligand in the Notch signaling
pathway that is highly expressed in tumors of neuroendocrine
origin but not in normal tissues1,2. The Notch signaling pathway
regulates cell proliferation, differentiation, and cell death and may
have tumor-suppressive or oncogenic effects, depending on the
tissue microenvironment3. Suppression of the NOTCH gene has
been shown to promote oncogenesis in small cell lung cancer
(SCLC), medullary thyroid carcinoma (MTC), and pancreatic and
biliary neuroendocrine tumors3,4. Although the function of DLL3 is
not fully understood, it has been implicated in the inhibition of the
Notch signaling pathway in the regulation of cell development
and cell fate decisions3,5.
Neuroendocrine carcinomas (NEC) are a group of poorly
differentiated neuroendocrine neoplasms3 that commonly express
DLL3, with positive DLL3 expression observed in 65–74% of large
cell NEC and in 77% of castration-resistant neuroendocrine
prostate cancer (NEPC)6,7. In contrast, DLL3 expression is not
observed at a high prevalence in low-grade, well-differentiated
neuroendocrine tumors (NET). Due to the heterogeneity and rarity
of neuroendocrine neoplasms, they are understudied and poorly
understood3. Platinum-based chemotherapy is a standard ﬁrst-line
option for NEC, despite the lack of survival advantage demonstrated in randomized trial8–10. Overall survival (OS) in patients
with NEC is <18 months9–13. A signiﬁcant need beyond ﬁrst-line
therapy exists for novel therapeutic treatment options for patients
with NEC, and DLL3 is a potential therapeutic target.
In addition to NEC, other cancers have high DLL3 expression,
including melanoma, MTC, and glioblastoma (GBM)14. Patients
with metastatic melanoma are typically treated with immune

checkpoint inhibitors and BRAF and MEK inhibitors, which
produce high response rates with impressive durability. However,
metastatic melanoma will ultimately become refractory to these
therapies, and median progression-free survival (PFS) is <1 year
with these agents15,16. MTC makes up 1–2% of thyroid cancers,
and 10–15% of patients present with metastatic disease at
diagnosis. These patients are typically treated with a multikinase
inhibitor, such as cabozantinib or vandetanib, or with selpercatinib
or other RET inhibitors for those with RET-mutated tumors17.
However, new treatment options are needed for patients with
MTC who do not beneﬁt from or are intolerant to these agents.
GBM accounts for 54% of all gliomas, and initial treatment often
consists of surgery, radiation therapy, and systemic therapy18,19.
Only one-third of patients will survive for 1 year, and <5% of
patients will live beyond 5 years18. Given the response to currently
available treatments, novel approaches are needed to treat
patients with these types of cancers.
Rovalpituzumab tesirine (Rova-T) is a ﬁrst-in-class antibody-drug
conjugate that targets DLL3 to deliver a cytotoxic compound
directly to tumor cells. Rova-T is composed of a monoclonal DLL3
antibody linked to a DNA intercalating agent (pyrrolobenzodiazepine) via a protease-cleavable linker. In SCLC and large cell
neuroendocrine patient-derived xenograft models, Rova-T signiﬁcantly inhibited tumor growth compared with standard
platinum-based therapy by effectively targeting and eliminating
DLL3-positive tumor-initiating cells2. A phase I study
(NCT01901653) demonstrated Rova-T antitumor activity in
patients with recurrent SCLC20. The objective response rate
(ORR) was 31%, and the 1-year survival rate was 32%; the median
OS was 5.8 months in patients with tumors expressing a high level
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of DLL3. In the phase II TRINITY study (NCT02674568) of Rova-T in
patients with relapsed/refractory SCLC, the ORR was 14%, the
median PFS was 3.8 months, and the median OS was 5.7 months
in patients with tumors expressing a high-level DLL321.
Given the activity of Rova-T observed in studies of SCLC and the
prevalence of DLL3 expression in solid tumors described above,
this study examined the safety, tolerability, and antitumor activity
of Rova-T in patients with DLL3-positive tumors, including NEC/
NET, melanoma, MTC, GBM, and other solid tumors.
RESULTS
Patient demographics, baseline characteristics, and
disposition
Between September 2016 and February 2019, 1293 patients were
pre-screened for DLL3-positive tumor status (Supplementary
Table 1); ~287 patients were ultimately screened for the study,
and 200 patients were subsequently enrolled and received at least
one dose of Rova-T. Disease-speciﬁc cohorts included both a doseescalation and expansion cohort. As of the data cutoff of October
14, 2019, patients had received a median of one cycle of therapy
(range, 1‒5); 96 patients (48%) had received two or more cycles of
Rova-T.
There were 101 patients with NEC/NET (pulmonary and
extrapulmonary large cell NEC [n = 13], NEPC [n = 21], highgrade gastroenteropancreatic [GEP] NEC [n = 36], and other NEC/
NET [n = 31]) and 99 patients with other solid tumors (melanoma
[n = 20], MTC [n = 13], GBM [n = 23], and other [n = 43]).
Supplementary Table 2 provides a breakdown of primary
diagnosis for other NEC/NET. The median age was 61 (range,
28‒84) years, and 94% of patients had stage IV disease at study
entry (Table 1). Seventy-seven (39%) patients had tumors
expressing a high level of DLL3, which was deﬁned as ≥50%
DLL3-positive cells. Most patients (55%) had received three or
more prior therapies. The median duration of follow-up was 4.6
(range, 0.1–33.7) months in all patients and 4.7 (range 0.1–27.1)
months in patients treated at the recommended phase 2 dose
(RP2D) of 0.3 mg/kg. The experience of one patient was described
previously22.
Rova-T was administered at dose levels of 0.2 mg/kg (n = 43),
0.3 mg/kg (n = 145), and 0.4 mg/kg (n = 12). Reasons for discontinuation of Rova-T included disease progression (n = 58, 29%),
adverse events (AEs) (n = 48, 24%), investigator decision (n = 21,
11%), withdrawn consent (n = 24, 12%), and other reasons
(treatment completed: n = 14, 7%; clinical progression: n = 10,
5%; withdrawn for hospice or other treatment: n = 3, 2%; lost to
follow-up: n = 2, 1%; noncompliance: n = 2, 1%; death: n = 1, 1%;
and unknown reasons: n = 17, 9%).
Dose escalation ﬁndings: dose-limiting toxicities (DLTs) and
RP2D
Overall, seven DLTs were experienced by ﬁve patients in this
study. At the 0.2-mg/kg dose level, two of 43 (5%) patients
experienced DLTs, including one patient with grade 3 photosensitivity reaction and one patient with grade 3 dyspnea. Two of
145 (3%) patients in the 0.3-mg/kg dose level had DLTs, including
one patient with grade 2 effusion and one patient with grade 3
rhabdomyolysis, grade 3 tumor lysis syndrome, and grade 4
kidney injury. One of 12 (8%) patients treated at the 0.4-mg/kg
dose level had a DLT of grade 4 thrombocytopenia. Despite only
one DLT identiﬁed in the 0.4-mg/kg group, the safety data in
totality indicated that 0.4 mg/kg every six weeks (q6w) is not well
tolerated (Table 2). Of the 12 patients enrolled in that cohort, nine
of 12 (75%) patients had grade 3/4 AEs, and six experienced drugrelated serious AEs (SAEs), including one patient with grade 5
hepatic failure. Because of these safety ﬁndings, 0.3 mg/kg q6w for
two cycles was chosen as the RP2D.
npj Precision Oncology (2021) 74

Clinical safety
Most patients (144 of 145; 99%) treated with 0.3 mg/kg Rova-T had
at least one treatment-emergent AE (TEAE) (Table 3). The most
common all-grade TEAEs were fatigue in 75 patients (52%), nausea
in 53 patients (37%), and thrombocytopenia and pleural effusion
in 48 patients (33%) each. Grade 3/4 AEs occurred in 78 of 145
(54%) patients. Fifty-nine (42%) patients had SAEs (excluding
malignant neoplasm progression), most commonly pleural effusion (n = 7; 5%), pericardial effusion (n = 6; 4%), and dyspnea (n =
5; 3%; Supplementary Table 3). TEAEs of special interest were
pleural effusion (n = 48; 33%), peripheral edema (n = 44; 30%),
pericardial effusion (n = 38; 26%), photosensitivity reaction (n =
37; 26%), and pneumonitis (n = 3; 2%). For each of these, grade 3/
4 events occurred in <5% of the overall population (Supplementary Table 4). Overall, 31 (21%) patients discontinued treatment
due to TEAEs.
At the time of data cutoff, a total of 21 of 145 (14%) patients
who were treated at the 0.3-mg/kg dose level experienced a grade
5 TEAE; 14 of 145 (10%) patients had a grade 5 event of malignant
neoplasm progression, and one of 145 (<1%) patients had a grade
5 event of another malignancy. Six of 145 (4%) patients
experienced a TEAE leading to death that was not related to
disease progression or malignancy; grade 5 TEAEs that were not
related to disease progression or malignancy included two events
of pneumonitis, and one event each of multiple organ dysfunction, acute respiratory failure, hepatic encephalopathy, devicerelated infection, and acute kidney injury (Supplementary Table 5).
Four of 145 (3%) patients had AEs leading to death that were
related to Rova-T, including two who died of pneumonitis, one
who died of acute respiratory failure, and one who died of hepatic
encephalopathy.
Efﬁcacy
One hundred forty-ﬁve patients received at least one dose of
Rova-T at 0.3 mg/kg and were included in the efﬁcacy analyses
(Table 4). The median follow-up for patients treated at 0.3 mg/kg
was 4.7 months (range, 0.1–27.1). Overall, the ORR was 10%,
including one complete response (CR) and 14 partial responses
(PRs), and the best overall response (BOR) rate was 17% (25/145;
one CR and 24 PRs). In pooled patients with NEC/NET, the ORR was
13% (9/69; all PRs) and the BOR rate was 25% (17/69; all PRs)
(Supplementary Table 6). The median PFS was 4.1 months (95% CI,
2.8–4.8), and the median OS was 7.1 months (95% CI, 5.6–9.7) in
pooled patients with NEC/NET. Efﬁcacy for 43 patients treated with
Rova-T at 0.2 mg/kg and 12 patients treated at 0.4 mg/kg is
reported in Supplementary Tables 7 and 8. The best change in
tumor lesion size in patients in each cohort is shown in
Supplementary Figs. 1–8.
In pooled patients with NEC/NET expressing a high level of DLL3
(≥50% DLL3-positive tumor cells), the ORR was 17% (6/35) and
34% (12/35) had a BOR (all PRs). In those with NEC/NET expressing
a low level of DLL3 (1–49% DLL3-positive tumor cells), the ORR
was 9% (3/34) and the BOR rate was 15% (5/34) (all PRs; Table 5).
The median PFS values for pooled patients with NEC/NET
expressing high and low levels of DLL3 were 4.3 months (95%
CI, 2.7–6.1) and 3.3 months (95% CI, 2.4–4.8), respectively. The
median OS values for patients expressing high and low levels of
DLL3 were 7.4 months (95% CI, 5.6–13.1) and 7.1 months (95% CI,
4.3–9.9), respectively.
DISCUSSION
In this multicenter, open-label, phase I/II study, the safety and
efﬁcacy of Rova-T monotherapy were evaluated at three dose
levels across advanced solid tumors with DLL3 expression.
Patients treated at the 0.2-mg/kg and 0.3-mg/kg dose levels had
fewer drug-related SAEs (21% and 23%, respectively) compared
Published in partnership with The Hormel Institute, University of Minnesota
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Table 1.

Patient demographics and baseline characteristics.

Characteristic

Melanoma
(n = 20)

MTC
(n = 13)

GBM
(n = 23)

Other solid
tumor (n = 43)

Pooled NEC/NET
(n = 101)

All treated
patients (N = 200)

Median age (range), years

63.5 (40–78)

60 (33–67)

57 (36–72)

64 (28–84)

61 (28–82)

61 (28–84)

Male sex, n (%)

10 (50)

8 (62)

19 (83)

23 (53)

66 (65)

126 (63)

ECOG performance status, n (%)
0

7 (35)

1 (8)

1 (4)

5 (12)

20 (20)

34 (17)

1

13 (65)

12 (92)

22 (96)

38 (88)

80 (79)

165 (83)

2

0

0

0

0

1 (1)

1 (1)

Disease stage at study entry
Stage IIa

1 (5)

0

0

0

0

1 (1)

Stage IIb

0

0

0

2 (5)

0

2 (1)

Stage IIIa

0

0

0

1 (2)

3 (3)

4 (2)

Stage IIIb

0

0

0

0

2 (2)

2 (1)

Stage IIIc

1 (5)

0

0

1 (2)

0

2 (1)

Stage IV

18 (90)

12 (92)

23 (100)

39 (91)

95 (94)

187 (94)

Missing

0

1 (8)

0

0

1 (1)

2 (1)

DLL3 level, n (%)
High (≥50%)

5 (25)

6 (46)

2 (9)

11 (26)

53 (52)

77 (39)

Low (1–49%)

14 (70)

7 (54)

21 (91)

32 (74)

48 (48)

122 (61)

0%

1 (5)a

0

0

0

0

1 (0.5)

1

3 (15)

4 (31)

2 (9)

6 (14)

22 (22)

37 (19)

2

4 (20)

4 (31)

7 (30)

10 (23)

25 (25)

50 (25)

3

5 (25)

0

6 (26)

8 (19)

27 (27)

46 (23)

≥4
Missing

8 (40)
0

2 (15)
3 (23)

8 (35)
0

19 (44)
0

27 (27)
0

64 (32)
3 (2)
57 (29)

Prior lines of therapy, n (%)

Response to ﬁrst-line therapy, n (%)b
Sensitivec

4 (20)

1 (8)

4 (17)

15 (35)

33 (33)

Resistantd

3 (15)

4 (31)

4 (17)

3 (7)

17 (17)

31 (16)

Refractorye

7 (35)

2 (15)

5 (22)

12 (28)

19 (19)

45 (23)

Undetermined

6 (30)

6 (46)

10 (43)

13 (30)

32 (32)

67 (34)

a

The patient had two DLL3 results; the result with a value of 0 was the latest value before enrollment and therefore was used in the analysis.
b
Refers to platinum-based therapy only.
c
Sensitive is deﬁned as a ﬁrst-line response that is neither refractory nor undetermined, and the start date of second-line treatment is ≥90 days after the end of
the ﬁrst-line treatment31.
d
Resistant is deﬁned as a ﬁrst-line response that is neither refractory nor undetermined, and the start date of second-line treatment is <90 days after the end of
the ﬁrst-line treatment31.
e
Refractory if a ﬁrst-line response is a progressive disease.

Table 2.

Summary of overall safety by dose.

AE, n (%)

0.2 mg/kg
(n = 43)

0.3 mg/kg
(n = 145)

0.4 mg/kg
(n = 12)

All
(N = 200)

Any TEAE

42 (98)

144 (99)

12 (100)

198 (99)

Grade 3/4 TEAE

30 (70)

78 (54)

9 (75)

117 (59)

Drug-related TEAE

37 (86)

132 (91)

12 (100)

181 (91)

Drug-related grade 20 (47)
3/4 TEAE

70 (48)

7 (58)

97 (49)

SAE

26 (60)

77 (53)

8 (67)

111 (56)

Drug-related SAEs

9 (21)

34 (23)

6 (50)

49 (25)

TEAE leading
to death

4 (9)

21 (14)

2 (17)

27 (14)

Drug-related TEAE
leading to death

0

4 (3)

2 (17)

6 (3)

Published in partnership with The Hormel Institute, University of Minnesota

with those treated at 0.4 mg/kg (50%). Patients treated at the
lower dose levels also had fewer drug-related TEAEs leading to
death (0–3%) compared with those treated at 0.4 mg/kg (17%).
Accordingly, the RP2D of Rova-T was chosen as 0.3 mg/kg q6w for
two cycles with the option of treatment beyond two cycles or
retreatment upon progression based on individual risk-beneﬁt
balance. The TEAEs reported in this study were similar to those
observed previously with Rova-T in patients with relapsed/
refractory SCLC20,21. High rates of pleural effusion, peripheral
edema, pericardial effusion, and photosensitivity were observed in
patients treated at 0.3 mg/kg. The rate of any-grade pericardial
effusion in this study (26%) was higher than reported in previous
studies of Rova-T (14–16%)20,21. Grade 3/4 TEAEs of special interest
occurred at low rates. Overall, Rova-T at 0.3 mg/kg q6w had a
more manageable toxicity proﬁle than did 0.4 mg/kg for the
majority of patients, and no appreciable differences in toxicity
proﬁles were observed across the tumor types evaluated. Owing
npj Precision Oncology (2021) 74
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Table 3.

TEAEs in >15% at any grade in all patients treated at the 0.3-mg/kg dose.

Preferred term,
n (%)

MTC (n = 10)

Melanoma
(n = 17)
All

Grade 3/4 All

GBM (n = 18)

Grade 3/4 All

Other solid tumor
(n = 31)

Grade 3/4 All

Pooled NEC/NET
(n = 69)

Grade 3/4 All

All patients treated
at 0.3 mg/kg
(N = 145)

Grade 3/4 All

Grade 3/4

Any TEAE

16 (94) 8 (47)

10 (100) 6 (60)

18 (100) 8 (44)

31 (100) 16 (52)

69 (100) 40 (58)

Fatigue

9 (53)

1 (6)

4 (40)

0

10 (56)

1 (6)

13 (42)

2 (6)

39 (57)

2 (3)

144 (99) 78 (54)
75 (52)

6 (4)

Nausea

5 (29)

0

3 (30)

0

4 (22)

1 (6)

12 (39)

2 (6)

29 (42)

2 (3)

53 (37)

5 (3)

Thrombocytopenia

2 (12)

0

2 (20)

1 (10)

3 (17)

1 (6)

11 (35)

4 (13)

30 (43)

16 (23)

48 (33)

22 (15)

Pleural effusion
Peripheral edema

6 (35)
5 (29)

0
0

3 (30)
3 (30)

0
0

5 (28)
3 (17)

0
0

7 (23)
9 (29)

2 (6)
0

27 (39)
24 (35)

2 (3)
1 (1)

48 (33)
44 (30)

4 (3)
1 (1)

Decreased appetite 6 (35)

0

0

0

3 (17)

1 (6)

11 (35)

1 (3)

22 (32)

1 (1)

42 (29)

3 (2)

Anemia

3 (18)

0

1 (10)

1 (10)

1 (6)

1 (6)

14 (45)

9 (29)

24 (35)

13 (19)

43 (30)

24 (17)

Dyspnea

5 (29)

1 (6)

5 (50)

2 (20)

3 (17)

0

6 (19)

1 (3)

21 (30)

0

40 (28)

4 (3)

Pericardial effusion

5 (29)

0

4 (40)

1 (10)

5 (28)

1 (6)

5 (16)

1 (3)

19 (28)

2 (3)

38 (26)

5 (3)

Photosensitivity
reaction

5 (29)

0

5 (50)

0

5 (28)

0

6 (19)

0

16 (23)

3 (4)

37 (26)

3 (2)

Vomiting

3 (18)

0

1 (10)

0

6 (33)

1 (6)

8 (26)

2 (6)

15 (22)

2 (3)

33 (23)

5 (3)

Abdominal pain

2 (12)

0

2 (20)

1 (10)

2 (11)

0

6 (19)

1 (3)

18 (26)

3 (4)

30 (21)

5 (3)

Aspartate
aminotransferase
elevation

0

0

2 (20)

2 (20)

3 (17)

0

5 (16)

2 (6)

19 (28)

8 (12)

29 (20)

12 (8)

Constipation

2 (12)

0

2 (20)

0

1 (6)

0

5 (16)

0

19 (28)

1 (1)

29 (20)

1 (1)

Alanine
aminotransferase
elevation

0

0

3 (30)

1 (10)

3 (17)

1 (6)

3 (10)

0

17 (25)

6 (9)

26 (18)

8 (6)

Cough

3 (18)

0

2 (20)

0

2 (11)

0

4 (13)

0

14 (20)

0

25 (17)

0

Diarrhea

3 (18)

0

0

0

2 (11)

0

4 (13)

1 (3)

14 (20)

2 (3)

23 (16)

3 (2)

Table 4.

Efﬁcacy at the 0.3-mg/kg dose.

Outcome
ORR, n (%) (95% CI)

Melanoma (n = 17)

MTC (n = 10)

GBM (n = 18)

Other solid tumor (n = 31)

Pooled NEC/NET (n = 69)
9 (13) (6.1–23.3)

1 (5.9) (0.1–28.7)

2 (20.0) (2.5–55.6)

1 (5.6) (0.1–27.3)

2 (6.5) (0.8–21.4)

CR

0

0

1 (5.6)

0

0

PR

1 (5.9)

2 (20.0)

0

2 (6.5)a

9 (13)

BOR, n (%)

2 (11.8)

2 (20.0)

1 (5.6)

3 (9.7)

17 (24.6)

CR

0

0

1 (5.6)

0

0

PR

2 (11.8)

2 (20.0)

0

3 (9.7)

17 (24.6)

Median DOR (95% CI), monthsb

2.9 (NE–NE)

NR (4.5–NE)

4.6 (NE–NE)

3.9 (0.4–4.1)

3.1 (2.3–NE)

Median PFS (95% CI), months
Median OS (95% CI), months

2.9 (1.3–3.7)
6.4 (3.3–12.8)

11.7 (1.3–NE)
NR (6.0–NE)

1.4 (1.2–2.5)
6.6 (2.8–9.7)

1.8 (1.3–4.0)
4.9 (3.9–5.9)

4.1 (2.8–4.8)
7.1 (5.6–9.7)

NE not estimable, NR not reached.
a
Patients with conﬁrmed PRs in the “Other solid tumor” category include 1 with neuroendocrine carcinoma of the lung and 1 with small cell carcinoma of the
esophagus.
b
DOR is deﬁned as the time from the ﬁrst assessment on therapy of a CR or PR to the date of disease progression.

to the small sample sizes, it is not possible to conclude whether
small differences in the toxicity proﬁles between different tumor
types or between the 0.2 mg/kg and 0.3 mg/kg dose levels were
statistically signiﬁcant; however, the 0.4 mg/kg dose was clearly
more toxic. Strategies to mitigate toxicity that were utilized in this
study included premedication with steroids, educating investigators on important risks (pleural/pericardial effusions, edema,
photosensitivity, and pneumonitis), reminding investigators to
closely monitor for risks and manage with standard clinical
practice, and sharing of best practices among investigators.
npj Precision Oncology (2021) 74

Toxicities associated with Rova-T treatment, including pleural
and pericardial effusions, may be caused in part by the
pyrrolobenzodiazepine component of the antibody-drug conjugate. While the mechanism is not fully understood, studies
suggest that systemic release or bystander effect may be
involved22–24. Systemic release occurs when premature cleavage
of the linker results in the release of the drug into circulation,
causing off-target toxicities. Bystander effect is the diffusion of the
drug from the target cell to neighboring cells that do not have the
target protein, either by leaking from the targeted cell or cleavage
Published in partnership with The Hormel Institute, University of Minnesota
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Table 5.

Efﬁcacy for DLL3-high and DLL3-low expression in Pooled
NEC/NET at the 0.3-mg/kg dose.

Outcome

Pooled NEC/NET
DLL3 high (n = 35) DLL3 low (n = 34)

ORR (95% CI), n (%)
CR

3 (8.8) (1.9–23.7)
0

METHODS
Patients

6 (17.1)

3 (8.8)

12 (34.3)

5 (14.7)

CR

0

0

PR

12 (34.3)

5 (14.7)

2.9 (1.2–NE)

NR (3.7–NE)

Adult patients with unresectable, refractory, advanced solid tumors other
than SCLC who were positive for DLL3 and had measurable disease were
included in the study. DLL3 positivity was deﬁned as immunohistochemical staining in ≥1% of tumor cells. Potential patients were pre-screened for
DLL3 positivity to determine initial eligibility, and those with DLL3-positive
tumors underwent full screening for study eligibility upon disease
progression. Measurable disease was deﬁned based on Response
Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)30. Patients
had to have an Eastern Cooperative Oncology Group (ECOG) performance
status of 0 to 1, a life expectancy of ≥12 weeks, and satisfactory laboratory
parameters. Patients could not have a clinically signiﬁcant medical
condition, including uncontrolled hypertension and/or diabetes, pulmonary disease, neurological disorder, recent or ongoing serious infection, or a
cerebral vascular event within six months of starting the study. Prior
exposure to pyrrolobenzodiazepine-containing drugs, including Rova-T,
was not allowed. All patients provided written informed consent.

PR
BOR, n (%)

Median DOR (95% CI),
monthsa

6 (17.1) (6.6–33.6)
0

and-development-program.htm; https://news.abbvie.com/news/
phase-3-trial-rova-t-as-second-line-therapy-for-advanced-small-celllung-cancer-tahoe-study-halted.htm). However, DLL3 remains a
relevant anticancer target. Additional strategies targeting DLL3 in
these difﬁcult-to-treat tumor types warrant investigation.

Median PFS (95% CI), months 4.3 (2.7–6.1)

3.3 (2.4–4.8)

Median OS (95% CI), months

7.1 (4.3–9.9)

7.4 (5.6–13.1)

NE not estimable.
a
DOR is deﬁned as the time from the ﬁrst assessment on therapy of a CR or
PR to the date of disease progression.

of the drug before it is internalized. In either case, DLL3-negative
cells may be inappropriately exposed to pyrrolobenzodiazepine,
and further reﬁnement of the linker or the drug-antibody ratio
may mitigate these effects.
This study enrolled a heavily pretreated population of patients
with DLL3-expressing tumors, and 55% of patients received at
least three prior lines of therapies. These ﬁndings demonstrate
that Rova-T as a single agent had antitumor activity in a subset of
heavily pretreated patients with tumor types that express DLL3,
including NEC/NET, melanoma, and MTC. These tumor types tend
to be treatment refractory following multiple prior lines of
therapy, and this may have contributed to the low response rate.
In addition, although DLL3 expression by IHC was required for
study entry, intratumoral variability in DLL3 expression may have
limited the overall antitumor activity of Rova-T. The median PFS
and OS in the patients in this study with the refractory disease
were similar to ranges shown in previous studies25–28.
Despite the limited sample size, a trend toward a higher
response rate was observed among patients with NEC/NET with
high DLL3 expression, supporting DLL3 as a promising therapeutic
target for the treatment of NEC/NET across primary disease sites,
including treatment-emergent NEPC. For pooled patients with
NEC/NET, the duration of response (DOR) of 3.1 months appears
comparable to the efﬁcacy with common treatment for these
tumor types in the relapsed or refractory setting29. These ﬁndings
are of particular interest for patients with recurrent NEC, for which
there is no standard-of-care treatment. Of note, the category of
grade 3 NET was not established for pancreatic and gastrointestinal NET for most of the study enrollment, therefore it is not
known whether any patients with grade 3 GEP NET were part of
the study. The majority of patients who were enrolled in the other
NEC/NET cohort were classiﬁed as having NEC, so it was not
possible to determine whether there was a difference in DLL3
expression in NET versus NEC.
Overall, reﬁnement of both the drug-antibody ratio and the linker
in Rova-T could improve drug delivery, reduce toxicity, and increase
treatment duration, which could lead to improved efﬁcacy. Further
study is needed to deﬁne the risk-beneﬁt balance of Rova-T in
patients with NEC/NET. During the conduct of the current trial, further
development of Rova-T was discontinued based on results from two
phase III studies that indicated a lack of favorable risk-beneﬁt balance
of Rova-T in patients with SCLC (https://news.abbvie.com/news/pressreleases/abbvie-discontinues-rovalpituzumab-tesirine-rova-t-researchPublished in partnership with The Hormel Institute, University of Minnesota

Study design and objectives
This multicenter, open-label, phase I/II study (NCT02709889) enrolled
patients in the United States. The study was conducted according to the
Declaration of Helsinki and all applicable laws, rules, and regulations within
the relevant jurisdictions of the investigators; the study was approved by
the institutional review boards at each participating institution. Patients
were enrolled in disease-speciﬁc cohorts, including melanoma, MTC, GBM,
large-cell NEC, NEPC, GEP NEC, other NEC/NET, and other solid tumors.
Dosing was predetermined to start at 0.2 mg/kg q6w, which is one dose
level below the RP2D for SCLC, with dose escalation continuing through
0.4 mg/kg, the maximum tolerated dose for SCLC20. In Part A, the RP2D was
determined in disease-speciﬁc cohorts. Part B tested the RP2D determined
in Part A in disease-speciﬁc expansion cohorts. The primary endpoint was
safety. Secondary endpoints included BOR, ORR, DOR, PFS, and OS. The
relationship between DLL3 expression and clinical outcome was tested as
an exploratory endpoint.

Treatment and assessments
DLL3 expression was determined at baseline with fresh or archived tumor
tissue using an SC16.65 mouse antibody IHC investigational use only (IUO)
assay developed by Ventana Medical Systems as previously described, at a
concentration of 0.78 µg/ml (AbbVie Stemcentrix, Lot No. 170420)20,21. Rova-T
was administered intravenously on day 1 of each 6-week cycle at 0.2, 0.3, or
0.4 mg/kg with a 3 + 3 design for dose escalation in Part A. Patients received
treatment until disease progression or unacceptable toxicity in Part A. Patients
in Part B received two doses and could receive further doses at the discretion
of the investigator. Dosing interval and duration were selected based on
previous clinical studies of Rova-T in SCLC20,21. Dexamethasone (8 mg) was
administered orally twice daily on the day before treatment with Rova-T and
on days 1 and 2 of treatment in each cycle. Rova-T dose reductions were
allowed. DLTs were evaluated in the DLT evaluation period, which occurred
during the ﬁrst three weeks of the ﬁrst cycle of treatment. DLTs were deﬁned
as grade 4 thrombocytopenia (or grade 3 with bleeding) lasting >7 days or
requiring platelet transfusion, grade 4 neutropenia lasting >7 days and/or
requiring growth factor support, any febrile neutropenia, grade 4 anemia
unrelated to underlying disease, clinically signiﬁcant grade 3/4 nonhematologic laboratory abnormalities lasting >7 days, and grade 3/4 nonlaboratory
AEs with the exception of fatigue, asthenia, nausea, or other constitutional
symptoms. Grade ≥3 AEs clearly unrelated to study drug and grade ≥3 AEs of
isolated alkaline phosphatase, amylase, or lipase laboratory abnormalities
were not considered DLTs.
Disease assessments involved computed tomography (CT) scans of the
chest, abdomen, pelvis, and neck (if indicated) and were conducted q6w
during active study treatment for 24 weeks and every 12 weeks thereafter
until disease progression. MRI scans of the brain were conducted if central
nervous system progression was previously documented, and CT scans
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with intravenous contrast could be substituted at the discretion of the
investigator. Patients with prostate cancer underwent whole-body
technetium-99m bone scintigraphy. Tumor response was assessed by
investigators according to RECIST v1.1, Response Assessment in NeuroOncology criteria for GBM, and Prostate Cancer Clinical Trials Working
Group 3 (PCWG3) for prostate cancer30. AEs were summarized using
preferred terms from the Medical Dictionary for Regulatory Activities and
graded using the National Cancer Institute’s Common Terminology Criteria
for Adverse Events version 4.03.

Statistical analysis
The planned enrollment was ~144 patients in dose escalation and ~174
patients in dose expansion to detect an ORR of 15%, which would indicate
efﬁcacy worthy of further investigation. Efﬁcacy was assessed by disease
and cohort and included all patients who received at least one dose of
Rova-T. BOR (deﬁned as the best response of CR or PR, with conﬁrmation
not required), ORR (conﬁrmed response), and DOR were summarized for all
patients with a CR or PR according to RECIST v1.1 or PCWG3. DOR, PFS, and
OS were evaluated using the Kaplan–Meier method. For DOR and PFS,
patients were censored at the time at which they received another cancer
therapy, missed two tumor assessments in a row, or had their last
evaluable response assessment if not PD or death. Safety assessments
were performed in all patients who received at least one dose of Rova-T.

Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.

DATA AVAILABILITY
AbbVie is committed to responsible data sharing regarding the clinical trials we
sponsor. This includes access to anonymized, individual, and trial-level data (analysis
data sets), as well as other information (e.g., protocols and Clinical Study Reports), as
long as the trials are not part of an ongoing or planned regulatory submission. This
includes requests for clinical trial data for unlicensed products and indications.
This clinical trial data can be requested by any qualiﬁed researchers who engage in
rigorous, independent scientiﬁc research and will be provided following review and
approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a
Data Sharing Agreement (DSA). Data requests can be submitted at any time, and the
data will be accessible for 12 months, with possible extensions considered. For more
information on the process, or to submit a request, visit the following link: https://
www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-informationsharing/data-and-information-sharing-with-qualiﬁed-researchers.html.

Received: 15 October 2020; Accepted: 14 July 2021;

REFERENCES
1. Chapman, G., Sparrow, D. B., Kremmer, E. & Dunwoodie, S. L. Notch inhibition by
the ligand DELTA-LIKE 3 deﬁnes the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. Hum. Mol. Genet. 20, 905–916 (2011).
2. Saunders, L. R. et al. A DLL3-targeted antibody-drug conjugate eradicates highgrade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl. Med. 7,
302ra136 (2015).
3. von Arx, C. et al. Updates on the role of molecular alterations and NOTCH signalling in the development of neuroendocrine neoplasms. J. Clin. Med. 8, https://
doi.org/10.3390/jcm8091277 (2019).
4. Lim, J. S. et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer. Nature 545, 360–364 (2017).
5. Dunwoodie, S. L., Henrique, D., Harrison, S. M. & Beddington, R. S. Mouse Dll3: a
novel divergent Delta gene which may complement the function of other Delta
homologues during early pattern formation in the mouse embryo. Development
124, 3065–3076 (1997).
6. Hermans, B. C. M. et al. DLL3 expression in large cell neuroendocrine carcinoma
(LCNEC) and association with molecular subtypes and neuroendocrine proﬁle.
Lung Cancer 138, 102–108 (2019).
7. Puca, L. et al. Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. Sci. Transl. Med. 11, https://doi.org/10.1126/
scitranslmed.aav0891 (2019).

npj Precision Oncology (2021) 74

8. Zhang, P. et al. Etoposide and cisplatin versus irinotecan and cisplatin as the ﬁrstline therapy for patients with advanced, poorly differentiated gastroenteropancreatic neuroendocrine carcinoma: a randomized phase 2 study.
Cancer 126, 2086–2092 (2020).
9. Yamaguchi, T. et al. Multicenter retrospective analysis of systemic chemotherapy
for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci. 105,
1176–1181 (2014).
10. Mitry, E. et al. Treatment of poorly differentiated neuroendocrine tumours with
etoposide and cisplatin. Br. J. Cancer 81, 1351–1355 (1999).
11. Hainsworth, J. D., Spigel, D. R., Litchy, S. & Greco, F. A. Phase II trial of paclitaxel,
carboplatin, and etoposide in advanced poorly differentiated neuroendocrine
carcinoma: a Minnie Pearl Cancer Research Network study. J. Clin. Oncol. 24,
3548–3554 (2006).
12. Sorbye, H. et al. Predictive and prognostic factors for treatment and survival in
305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO
G3): the NORDIC NEC study. Ann. Oncol. 24, 152–160 (2013).
13. Welin, S. et al. Clinical effect of temozolomide-based chemotherapy in poorly
differentiated endocrine carcinoma after progression on ﬁrst-line chemotherapy.
Cancer 117, 4617–4622 (2011).
14. Spino, M. et al. Cell surface notch ligand DLL3 is a therapeutic target in isocitrate
dehydrogenase-mutant glioma. Clin. Cancer Res. 25, 1261–1271 (2019).
15. Dummer, R. et al. Cutaneous melanoma: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up. Ann. Oncol. 26, v126–v132 (2015).
16. Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N.
Engl. J. Med. 372, 2521–2532 (2015).
17. Randle, R. W. et al. Trends in the presentation, treatment, and survival of patients
with medullary thyroid cancer over the past 30 years. Surgery 161, 137–146
(2017).
18. Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and central nervous
system tumors diagnosed in the United States in 2006-2010. Neuro. Oncol. 15,
ii1–ii56 (2013).
19. Stupp, R. et al. High-grade glioma: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann. Oncol. 25, iii93–iii101 (2014).
20. Rudin, C. M. et al. Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a ﬁrst-in-human, ﬁrst-in-class, openlabel, phase 1 study. Lancet Oncol. 18, 42–51 (2017).
21. Morgensztern, D. et al. Efﬁcacy and safety of rovalpituzumab tesirine in third-line
and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung
cancer: results from the phase II TRINITY study. Clin. Cancer Res., https://doi.org/
10.1158/1078-0432.CCR-19-1133 (2019).
22. Miller, M. L. et al. A DNA-interacting payload designed to eliminate cross-linking
improves the therapeutic index of antibody-drug conjugates (ADCs). Mol. Cancer
Ther. 17, 650–660 (2018).
23. Joubert, N., Beck, A., Dumontet, C. & Denevault-Sabourin, C. Antibody-drug
conjugates: the last decade. Pharmaceuticals 13, https://doi.org/10.3390/
ph13090245 (2020).
24. Khera, E. et al. Quantifying ADC bystander payload penetration with cellular
resolution using pharmacodynamic mapping. Neoplasia 23, 210–221 (2021).
25. Kam Kamiya-Matsuoka, C. & Gilbert, M. R. Treating recurrent glioblastoma: an
update. CNS Oncol. 4, 91–104 (2015).
26. Yamazaki, N. et al. Long-term follow up of nivolumab in previously untreated
Japanese patients with advanced or recurrent malignant melanoma. Cancer Sci.
110, 1995–2003 (2019).
27. Wells, S. A. Jr. et al. Revised American thyroid association guidelines for the
management of medullary thyroid carcinoma. Thyroid 25, 567–610 (2015).
28. Okuyama, H. et al. A phase II trial of everolimus in patients with advanced
pancreatic neuroendocrine carcinoma refractory or intolerant to platinumcontaining chemotherapy (NECTOR trial). Neuroendocrinology, https://doi.org/
10.1159/000505550 (2020).
29. Sugiyama, K. et al. Salvage chemotherapy by FOLFIRI regimen for poorly differentiated gastrointestinal neuroendocrine carcinoma. J Gastrointest. Canc., https://
doi.org/10.1007/s12029-020-00516-7 (2020).
30. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
31. Eckardt, J. R. et al. Phase III study of oral compared with intravenous topotecan as
second-line therapy in small-cell lung cancer. J. Clin. Oncol. 25, 2086–2092 (2007).

ACKNOWLEDGEMENTS
AbbVie and the authors thank the patients and their families, study coordinators, and
support staff, as well as the former AbbVie employees for contributions to the study.
Medical writing support was provided by Rohina Rubicz, Ph.D., of Bio Connections
LLC, funded by AbbVie. AbbVie sponsored the study and participated in the design,

Published in partnership with The Hormel Institute, University of Minnesota

AS Mansﬁeld et al.

7
study conduct, analysis, and interpretation of data, as well as the writing, review, and
approval of the publication. No honoraria or payments were made for authorship.

AUTHOR CONTRIBUTIONS
Conception and design: H.B., R.A. Provision of study materials or patients: A.F.F., H.
B., A.E.H., M.H.T., S.T.T., J.N., C.H.C., R.A. Collection and assembly of data: A.F.F., A.E.
H., M.H.T., S.T.T., J.N., C.H.C., C.L., Y.L., R.A. Data analysis and interpretation: A.E.H., M.
H.T., S.T.T., J.N., Y.L., R.A. Manuscript writing: all authors. Final approval of
manuscript: all authors.

COMPETING INTERESTS
A.S.M. reports honoraria to institution from AbbVie, AstraZeneca, Bristol Myers
Squibb, and Genentech; research funding from the National Institutes of Health,
Novartis, and Verily; nonremunerated director of Mesothelioma Applied Research
Foundation. D.S.H. reports a leadership role or other ownership with OncoResponse,
Molecular Match, and Presagia Inc.; a consultancy/advisory role for Alpha Insights,
Amgen, Axiom, Adaptimmune, Baxter, Bayer, eCancer, Genentech, GLG, Group H,
Guidepoint, Inﬁnity, Medscape, Numab, Oncology Education Project Association,
Pﬁzer, Prime Oncology, Takeda, Trieza Therapeutics, and WebMD; travel support from
Bayer, Loxo, miRNA, Genmab, AACR, ASCO, and SITC; research funding from AbbVie,
Adaptimmune, Aldi-Norte, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi
Sankyo, Eisai, Fate Therapeutics, Genentech, Genmab, GlaxoSmithKline, Ignyta,
Inﬁnity, Kite, Kyowa, Eli Lilly, Loxo Oncology, Merck, MedImmune, Mirati Therapeutics,
miRNA, Molecular Templates, MOLOGEN AG, NCI-CTEP, Novartis, Pﬁzer, Seattle
Genetics, Takeda, and Turning Point Therapeutics. C.L.H. reports a consultancy/
advisory role with AbbVie, Ascentage Pharma, Bristol Myers Squibb, and Genentech;
research funding to institution from AbbVie, Amgen, AstraZeneca, and Bristol Myers
Squibb. A.F.F. reports a consultancy/advisory role with Bayer, Loxo Oncology,
Genentech, Roche, Bristol Myers Squibb, AstraZeneca, AbbVie, PharmaMar, Boehringer Ingelheim, Merck, H3 Biomedicine, and Pﬁzer; research funding from Bayer, Loxo
Oncology, Genentech, Roche, Bristol Myers Squibb, AstraZeneca, AbbVie, PharmaMar,
Merck, Ignyta, Amgen, and Novartis; honoraria from DAVA Oncology, Clinical Care
Options, Medical Learning Institute, Medscape, PeerView, and Research to Practice. H.
B. reports a consultancy/advisory role with Janssen, Sanoﬁ Genzyme, Pﬁzer, Astellas,
AstraZeneca, and Merck; research funding from AbbVie/Stemcentrx; research funding
to institution from Janssen Oncology, Eli Lilly, and Millennium Pharmaceuticals. S.N.
W. reports research funding to institution from Spectrum Pharmaceuticals, Eli Lilly,
Pﬁzer, Roche/Genentech, Daiichi Sankyo, NewLink Genetics, EMD Serono, Puma
Biotechnology, Novartis, Xcovery, Synermore Biologics, Celgene, Vertex, Bristol Myers
Squibb, Stemcentrx, Hengrui Therapeutics, Checkpoint Therapeutics, Ignyta, AstraZeneca, ARIAD, Roche, and Merck. A.E.H. reports a consultancy/advisory role with
Novartis, Ipsen, Perthera, Celgene, and AbbVie; research funding from AbbVie; travel
accommodations from Halozyme. L.B.A. reports a consultancy/advisory role for
Lexicon; research funding to institution from AbbVie, Oncotelic, and Entrinsic Health
Solutions. M.H.T. reports a consultancy/advisory role with and honoraria from Bristol
Myers Squibb, Eisai, Novartis, Bayer, Sanoﬁ/Genzyme, Array Biopharma, Loxo
Oncology, Blueprint Medicines, and Arqule; speakers’ bureau for and honoraria from
Bristol Myers Squibb and Eisai. A.H.B. reports honoraria from Astellas Pharma and
Bayer; travel support from Clovis Oncology. S.T.T. reports a consultancy/advisory role
for Medivation, Astellas Pharma, Dendreon, Janssen, Bayer, Genentech, Endocyte,
Immunomedics, Karyopharm Therapeutics, AbbVie, Tolmar, QED Therapeutics,
Amgen, Sanoﬁ, Pﬁzer, Clovis Oncology, Novartis, and Genomic Health, POINT
Biopharma, Blue Earth Diagnostics, Aikido Pharma, Telix Pharma; travel support from

Published in partnership with The Hormel Institute, University of Minnesota

Sanoﬁ, Immunomedics, and Amgen; research funding to institution from Eli Lilly,
Sanoﬁ, Janssen, Astellas Pharma, Progenics, Millennium, Amgen, Bristol Myers Squibb,
Dendreon, Rexahn Pharmaceuticals, Bayer, Genentech, NewLink Genetics, Inovio
Pharmaceuticals, AstraZeneca, Immunomedics, Novartis, AVEO, Boehringer Ingelheim, Merck, Stemcentrx, Karyopharm Therapeutics, AbbVie, Medivation, Endocyte,
Exelixis, Clovis Oncology, SeaGen, and Gilead. K.L. reports a consultancy/advisory role
for Array BioPharma, Merck, Roche, and Regeneron; honoraria from Array BioPharma;
travel support from Merck, Roche/Genentech, and Regeneron; research funding to
the institution from Roche/Genentech, Merck, Array BioPharma, Incyte, Nektar,
Iovance Biotherapeutics, Bristol Myers Squibb, Kartos Therapeutics, OncoSec,
Regeneron, Alkermes, and Neon Therapeutics; uncompensated relationship with
Roche/Genentech and Regeneron. J.N. reports a consultancy/advisory role for Roche
and Boehringer Ingelheim; honoraria from Onclive. C.H.C. reports a consultancy/
advisory role for Bristol Myers Squibb, Mirati, CUE Biopharma, Sanoﬁ, and Ignyta;
travel support from Bristol Myers Squibb; research funding from AstraZeneca, Bristol
Myers Squibb, Eli Lilly, Merck, Regeneron, Ignyta, Brooklyn Therapeutics, Pﬁzer, and
lovance. J.M.C. reports research funding from Merck, AstraZeneca, Esperas Pharma,
and Tesaro; a consultancy/advisory role with Bristol Myers Squibb; travel funding
from Bristol Myers Squibb. M.R. reports former employment by AbbVie, current
employment with Calithera Biosciences, and may hold AbbVie stock. C.L., R.V., and Y.
L. report employment by AbbVie and may own stock or other options. R.A. reports a
consultancy/advisory role for AstraZeneca and Janssen; honoraria from Clovis
Oncology; travel support from Xynomic Pharmaceuticals; institution received
research funding from Zenith Epigenetics, Novartis, Xynomic Pharmaceuticals,
Cancer Targeted Technology, Janssen, Merck, and AbbVie.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41698-021-00214-y.
Correspondence and requests for materials should be addressed to R.A.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional afﬁliations.

Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.

© The Author(s) 2021

npj Precision Oncology (2021) 74

